Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1534–1541. doi: 10.1038/sj.bjc.6690245

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue

C M Ferrier 1, H H de Witte 2, H Straatman 3, D H van Tienoven 2, W L van Geloof 1, F J R Rietveld 1, C G J Sweep 2, D J Ruiter 1, G N P van Muijen 1
PMCID: PMC2362713  PMID: 10188903

Abstract

Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the two techniques are not directly interchangeable and that their value for clinical purposes may be different. © 1999 Cancer Research Campaign

Keywords: ELISA, immunohistochemistry, plasminogen activator system, correlation

Full Text

The Full Text of this article is available as a PDF (295.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Behrendt N., Rønne E., Ploug M., Petri T., Løber D., Nielsen L. S., Schleuning W. D., Blasi F., Appella E., Danø K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem. 1990 Apr 15;265(11):6453–6460. [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Christensen L., Wiborg Simonsen A. C., Heegaard C. W., Moestrup S. K., Andersen J. A., Andreasen P. A. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer. 1996 May 16;66(4):441–452. doi: 10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  5. Duggan C., Maguire T., McDermott E., O'Higgins N., Fennelly J. J., Duffy M. J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer. 1995 May 29;61(5):597–600. doi: 10.1002/ijc.2910610502. [DOI] [PubMed] [Google Scholar]
  6. Ferrier C. M., van Geloof W. L., de Witte H. H., Kramer M. D., Ruiter D. J., van Muijen G. N. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem. 1998 Apr;46(4):469–476. doi: 10.1177/002215549804600406. [DOI] [PubMed] [Google Scholar]
  7. Foekens J. A., Buessecker F., Peters H. A., Krainick U., van Putten W. L., Look M. P., Klijn J. G., Kramer M. D. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 1995 Apr 1;55(7):1423–1427. [PubMed] [Google Scholar]
  8. Ganesh S., Sier C. F., Heerding M. M., van Krieken J. H., Griffioen G., Welvaart K., van de Velde C. J., Verheijen J. H., Lamers C. B., Verspaget H. W. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer. 1996 Mar 15;77(6):1035–1043. doi: 10.1002/(sici)1097-0142(19960315)77:6<1035::aid-cncr5>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  9. Grebenschikov N., Geurts-Moespot A., De Witte H., Heuvel J., Leake R., Sweep F., Benraad T. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers. 1997 Jan-Mar;12(1):6–14. doi: 10.1177/172460089701200102. [DOI] [PubMed] [Google Scholar]
  10. Heiss M. M., Babic R., Allgayer H., Gruetzner K. U., Jauch K. W., Loehrs U., Schildberg F. W. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol. 1996 Feb;22(1):74–77. doi: 10.1016/s0748-7983(96)91649-2. [DOI] [PubMed] [Google Scholar]
  11. Hsu D. W., Efird J. T., Hedley-Whyte E. T. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol. 1995 Jul;147(1):114–123. [PMC free article] [PubMed] [Google Scholar]
  12. Kobayashi H., Fujishiro S., Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994 Dec 15;54(24):6539–6548. [PubMed] [Google Scholar]
  13. Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Jänicke F., Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401–409. doi: 10.1006/gyno.1994.1313. [DOI] [PubMed] [Google Scholar]
  14. Mulcahy H. E., Duffy M. J., Gibbons D., McCarthy P., Parfrey N. A., O'Donoghue D. P., Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 1994 Aug 27;344(8922):583–584. doi: 10.1016/s0140-6736(94)91968-2. [DOI] [PubMed] [Google Scholar]
  15. Pappot H., Skov B. G., Pyke C., Grøndahl-Hansen J. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. Lung Cancer. 1997 Jul;17(2-3):197–209. doi: 10.1016/s0169-5002(97)00032-9. [DOI] [PubMed] [Google Scholar]
  16. Ruiter D. J., Ferrier C. M., van Muijen G. N., Henzen-Logmans S. C., Kennedy S., Kramer M. D., Nielsen B. S., Schmitt M. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer. 1998 Aug;34(9):1334–1340. doi: 10.1016/s0959-8049(98)00151-8. [DOI] [PubMed] [Google Scholar]
  17. Rønne E., Behrendt N., Ellis V., Ploug M., Danø K., Høyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 1991 Aug 19;288(1-2):233–236. doi: 10.1016/0014-5793(91)81042-7. [DOI] [PubMed] [Google Scholar]
  18. Rønne E., Høyer-Hansen G., Brünner N., Pedersen H., Rank F., Osborne C. K., Clark G. M., Danø K., Grøndahl-Hansen J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995 Mar;33(3):199–207. doi: 10.1007/BF00665944. [DOI] [PubMed] [Google Scholar]
  19. Schmitt M., Thomssen C., Ulm K., Seiderer A., Harbeck N., Höfler H., Jänicke F., Graeff H. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer. 1997;76(3):306–311. doi: 10.1038/bjc.1997.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sier C. F., Fellbaum C., Verspaget H. W., Schmitt M., Griffioen G., Graeff H., Hôfler H., Lamers C. B. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology. 1991 Sep;19(3):231–237. doi: 10.1111/j.1365-2559.1991.tb00027.x. [DOI] [PubMed] [Google Scholar]
  21. Sweep C. G., Geurts-Moespot J., Grebenschikov N., de Witte J. H., Heuvel J. J., Schmitt M., Duffy M. J., Jänicke F., Kramer M. D., Foekens J. A. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer. 1998 Dec;78(11):1434–1441. doi: 10.1038/bjc.1998.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Thorpe S. M. Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res Treat. 1987;9(3):175–189. doi: 10.1007/BF01806378. [DOI] [PubMed] [Google Scholar]
  23. Umeda T., Eguchi Y., Okino K., Kodama M., Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol. 1997 Dec;183(4):388–397. doi: 10.1002/(SICI)1096-9896(199712)183:4<388::AID-PATH943>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  24. de Vries T. J., van Muijen G. N., Ruiter D. J. The plasminogen activation system in tumour invasion and metastasis. Pathol Res Pract. 1996 Jul;192(7):718–733. doi: 10.1016/S0344-0338(96)80094-X. [DOI] [PubMed] [Google Scholar]
  25. de Witte H., Pappot H., Brünner N., Grøndahl-Hansen J., Hoyer-Hansen G., Behrendt N., Guldhammer-Skov B., Sweep F., Benraad T., Danø K. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. Int J Cancer. 1997 Jul 29;72(3):416–423. doi: 10.1002/(sici)1097-0215(19970729)72:3<416::aid-ijc8>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES